ProEx™ C Biomarker by Immunohistochemistry
Test Code
I PROEXC or I PROEXC TC
Test Synonyms
Minichromosome Maintenance (MCM) and Topoisomerase II alpha (TOP2A) proteins
Associations
Aberrant S phase
Methodology
Immunohistochemistry
CPT Codes
88342 – Immunohistochemistry
Turnaround Time
3 days
Specimen Requirements
Formalin Fixed Paraffin Embedded (FFPE) tissue or cell block
Specimen Stability
18-25°C for 21 days
Storage & Handling
Ship at ambient temperature.
Causes for Rejection
Improper specimen labeling; Insufficient sample; Inadequate fixation
Reference Range
Cells positive for aberrant S phase induction not detected
Description
Results are reviewed by a board-certified pathologist to determine if tissues are positive or negative for proteins present in aberrant S-phase activity. These results may be used to assist in determining appropriate patient therapy or treatment.
ProExC is a cocktail of monoclonal antibodies that target the Minichromosome Maintenance (MCM) and Topoisomerase II alpha (TOP2A) proteins which, when over-expressed in the cell nucleus, are indicative of disease progression caused by aberrant S-phase induction in the DNA. Human papillomavirus oncoproteins E6 and E7 bypass the critical cell-cycle checkpoints resulting in a prolonged and aberrant S-phase induction cycle. During transcriptional activation of the aberrant cell cycle, levels of MCM2 and TOP2A proteins increase in proliferating cells.
References
- Press M, et al. (2002). Steroids 67: 799-813.
- Kastan M. and Bartek J. (2004). Cell-Cycle Checkpoints and Cancer. Nature, Vol. 432: 316-323.
- Massague J. (2004). G1 Cell Cycle Control and Cancer. Nature. Vol. 432: 298-306.
Trademarks
ProEx C is a registered trademark of Becton Dickinson & Company.
